| Display title | Chemistry:Imagabalin |
| Default sort key | Imagabalin |
| Page length (in bytes) | 4,229 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 825211 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>JOpenQuest |
| Date of page creation | 01:36, 6 February 2024 |
| Latest editor | imported>JOpenQuest |
| Date of latest edit | 01:36, 6 February 2024 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Imagabalin (INN, USAN; PD-0332334) was an investigational drug that acts as a ligand for the α2δ subunit of the voltage-dependent calcium channel, with some selectivity for the α2δ1 subunit over α2δ2. It was under development by Pfizer as a pharmaceutical medication due to its hypothesized anxiolytic... |
